Notes
MARKET UPDATES
CONSUMER
🔸 $BSET: Q1 EPS $0.21 (est. $0.03), rev $82.2M (est. $79.62M).
🔸 $LCID: Q1 production 2,212 vehicles, 600+ in transit; delivered 3,109; files to sell $1B in notes; guides Q1 revs $232M-$236M (est. $256.3M).
🔸 $LYFT: Downgraded to Underperform at BofA, tgt cut to $10.50.
🔸 $NKE, $ADDYY: Shares drop on new 46% Vietnam tariff (impacting AEO, W).
🔸 $RH: Q4 revs $812.4M (est. $829.6M), EPS $1.58 (est. $1.91); guides FY25 rev growth 10%-13%; warns of tariff risks.
🔸 $ROST, $TJX: Upgraded to Buy at Citi; tariffs boost off-price retail inventory.
ENERGY, INDUSTRIALS & MATERIALS
🔸 $BALL, $CCK: Potential impact from new 25% tariff on canned beer, aluminum.
🔸 $EMN: Upgraded to Outperform at Mizuho, tgt $105 (+18% upside).
🔸 $LSTR: Q1 EPS cut to $0.90-$0.95 (prior $1.05-$1.25) due to supply chain fraud.
🔸 $MSM: Q2 EPS $0.72 in line, revs $891.72M (est. $908.3M).
🔸 $PCAR: CFO Harrie Schippers to retire; Brice Poplawski promoted.
FINANCIALS
🔸 $RGP: Q3 adj. EBITDA $1.7M (est. -$0.5M), revs $129.4M (est. $130M).
HEALTHCARE
🔸 $RXST: Cuts FY25 rev view to $160M-$175M (prior $185M-$197M).
🔸 $SRNA: Files for $100M mixed shelf.
🔸 Drugmakers ($AZN, $SNY, $NVO): Spared from Trump tariffs, benefiting exporters.
🔸 Medical Devices ($DXCM, $GHHC, $BSX, $ABT): Under pressure due to new tariffs (34% China, 20% EU).
TECH, MEDIA & TELECOM
🔸 $MSFT: Pausing data center projects, impacting VRT, CRWV, ETN, SMCI, DELL, VST, SMR, OKLO, NRG, CEG.
🔸 $GCT: Increases buyback by $16M.
🔸 $PDD: Investing $13B over three years to support merchants.
🔸 $PENG: Q2 EPS $0.52 (est. $0.38), sales $366M (+29% y/y, est. $345.1M).
#Downgrades - Dec 18, 2024
• $AM: Wells Fargo Downgrades to Equal Weight from Overweight - PT $16
• $ANGI: JPMorgan Downgrades to Neutral from Overweight
• $AXTA: Citi Downgrades to Neutral from Buy - PT $41 (from $45)
• $AXTA: Citi Downgrades to Neutral from Buy - PT $41 (from $45)
• $EA: Stifel Downgrades to Hold from Buy - PT $167
• $EMN: Citi Downgrades to Neutral from Buy - PT $104 (from $118)
• $EMN: Citi Downgrades to Neutral from Buy - PT $104 (from $118)
• $EPD: Wells Fargo Downgrades to Equal Weight from Overweight - PT $35
• $FLNC: Baird Downgrades to Neutral from Outperform - PT $20 (from $24)
• $FLR: Baird Downgrades to Neutral from Outperform - PT $58 (from $54)
• $GETY: JPMorgan Downgrades to Underweight from Neutral
• $HAL: Barclays Downgrades to Equalweight from Overweight - PT $33 (from $43)
• $MTCH: JPMorgan Downgrades to Neutral from Overweight - PT $33 (from $40)
• $MYPS: JPMorgan Downgrades to Underweight from Neutral
• $OII: Barclays Downgrades to Equalweight from Overweight - PT $26 (from $22)
• $OKE: Wells Fargo Downgrades to Equal Weight from Overweight - PT $107
• $PAA: Wells Fargo Downgrades to Equal Weight from Overweight - PT $20
• $PAGP: Wells Fargo Downgrades to Equal Weight from Overweight - PT $20
• $PBA: Wells Fargo Downgrades to Equal Weight from Overweight
• $PTVE: Jefferies Downgrades to Hold from Buy - PT $18 (from $15)
• $RIVN: Baird Downgrades to Neutral from Outperform - PT $16 (from $18)
• $RNR: Jefferies Downgrades to Hold from Buy - PT $282 (from $304)
• $SBAC: BMO Capital Downgrades to Market Perform from Outperform - PT $230 (from $260)
• $VAL: Barclays Downgrades to Equalweight from Overweight - PT $49 (from $59)
#Upgrades - Nov 26, 2024
• $AIT: BofA Securities Upgrades to Buy from Neutral - PT $315 (from $285)
• $ALGT: UBS Upgrades to Neutral from Sell - PT $16
• $CHTR: BNP Paribas Upgrades to Neutral from Underperform - PT $360
• $CPRI: Guggenheim Upgrades to Buy from Neutral - PT $30
• $CORI: Guggenheim Upgrades to Buy from Neutral - PT $30
• $CVX: Citi Upgrades to Buy from Neutral - PT $185 (from $145)
• $EMN: Wells Fargo Upgrades to Overweight from Equal Weight - PT $125 (from $110)
• $HBI: UBS Upgrades to Buy from Neutral
• $ONB: Raymond James Upgrades to Strong Buy from Market Perform - PT $28
• $SAIC: Wells Fargo Upgrades to Overweight from Equal Weight - PT $147 (from $157)
• $UAL: UBS Upgrades to Buy from Neutral - PT $139
• $ZM: Evercore ISI Upgrades to Outperform from In Line - PT $115 (from $70)